References
- Derks M, Abt M, Phelan M, Turnbull L, Meneses-Lorente G, Bech N, White AM, Parr G. (2010a). Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug–drug interactions. J Clin Pharmacol 50:1188–1201.
- Derks M, Busse-Reid R, Kuhlmann O, Paehler A. (2010b). [14C]-Dalcetrapib ADME following a single oral dose in healthy male subjects. Clin Pharmacol Ther 87 (S9):S37 (abstract).
- Derks M, Fowler S, Kuhlmann O. (2009a). In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 25:891–902.
- Derks M, Fowler S, Kuhlmann O. (2009b). A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther 31:586–599.
- Kastelein JJ, Duivenvoorden R, Deanfield J, de Groot E, Jukema JW, Kaski JC, Münzel T, Taddei S, Lehnert V, Burgess T, Kallend D, Lüscher TF. (2011). Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr Med Res Opin 27:141–150.
- Kunta JR, Lee SH, Perry BA, Lee YH, Sinko PJ. (2004). Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. Drug Metab Dispos 32:1293–1298.
- Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. (2000). A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203–207.
- Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. (2009). Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 158:896–901.
- Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ. (2009). Safety and tolerability of dalcetrapib. Am J Cardiol 104:82–91.
- Ward KW, Proksch JW, Levy MA, Smith BR. (2001). Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics. Drug Metab Dispos 29:82–88.
- Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR. (2004). Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 32:172–177.